Highlights
- ImExHS (IME) sees revenue growth by 33% in FY 2024.
- Net loss narrows by 41% from the previous year.
- Radiology segment leads with 68% of total revenue.
ImExHS (ASX:IME) has reported its Full Year 2024 financial results, showcasing a significant 33% increase in revenue, reaching AU$26.5 million compared to the previous fiscal year. The company also improved its net loss to AU$2.63 million, narrowing the gap by 41% from FY 2023. Additionally, the loss per share has improved to AU$0.058 from AU$0.11 in FY 2023.
ImExHS Earnings Insights
The lion's share of ImExHS's revenue stems from its Radiology segment, which contributed AU$18.1 million, constituting 68% of the total revenue. However, the cost of sales, totaling AU$15.5 million, accounted for 59% of the total revenue, highlighting the challenges in operational earnings. A major component of expenses remains General & Administrative costs, amounting to AU$8.39 million or 62% of total expenses.
Market Outlook
Looking ahead, ImExHS's revenue is projected to grow annually by approximately 18% over the next three years, which is slightly below the forecasted 22% growth for the Australian Healthcare Services industry. As of now, the company’s shares have seen a slight dip of 1.3% over the past week.